COPY SUBMITTED IN IDS

ł

1

ļ

1

INTERNATIONAL SEARCH REPORT			International appli	mulication No	
				2004/005152	
Int.Cl According to Int B. FIELDS SE Minimum docum	CATION OF SUBJECT MATTER C12N15/09, C07K16/28, C07K16 A61P43/00, A61K39/395 ernational Patent Classification (IPC) or to both national ARCHED mentation searched (classification system followed by cl C12N15/09, C07K16/28, C07K16 A61P43/00, A61K39/395	al classification and IP	00, A61P37/0	02,	
Electronic data b	earched other than minimum documentation to the extension as a second during the international search (name of S, BIOSIS/WPI (DIALOG), SwissPro	data base and, where p	racticable, search te	rms used) ·	
C. DOCUMEN	ITS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where ap	propriate, of the relev	ant passages	Relevant to claim No.	
Y	Hudson P.J. et al., High avidity scFv multimers; diabodies and triabodies, J.Immunol.Methods, 1999, Vol.231, pages 177 to 189		1-14		
Y	Kortt A.A. et al., Dimeric ar bodies: high avidity scFvs fo ing, Biomol.Eng., 2001, Vol.1 108	or cancer tar	1-14		
Y	Xiong D. et al., Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody, Cancer Lett., 2002, Vol.177, pages 29 to 39			1-14	
× Further do	cuments are listed in the continuation of Box C.	See patent far	nily annex.		
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed 		 T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art & document member of the same patent family 			
Date of the actual completion of the international search 05 July, 2004 (05.07.04)		Date of mailing of the international search report 20 July, 2004 (20.07.04)			
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer			
Facsimile No.		Telephone No.			

Form PCT/ISA/210 (second sheet) (January 2004)

COPY SUBMITTED IN IDS

:

į

ļ

L

i

!

	INTERNATIONAL SEARCH REPORT	International appli	
0 (0 - + +		PC1/JP2	004/005152
	DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relev		Relevant to claim No.
Y	MATSUOKA S. et al., A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement, J.Exp.Med., 1995, Vol.181, pages 2007 to 2015		
Y	Fayen J. et al., Negative signaling by ar HLA class I antibodies is dependent upon triggering events, Int.Immunol., 1998, Vo pages 1347 to 1358	1-14	
Y	Woodle E.S. et al., Anti-human class I MM antibodies induce apoptosis by a pathway is distinct from the Fas antigen-mediated way, J.Immunol., 1997, Vol.158, pages 215 2164	1-14	
Y	Tahtis k. et al., Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2), constructs in a breast carcinoma xenograft model, Clin.Cancer Res., 2001, Vol.7, pages 1061 to 1072		1-14
Y	Rossi E.A. et al., Development of new multi valent-bispecific agents for pretargeting tumor localization and therapy, Clin.Cancer Res., 2003, Vol.9, pages 3886S to 3896S		1-14
E,X	WO 04/033499 A1 (Chugai Pharmaceutical C Ltd.), 22 April, 2004 (22.04.04), Full text (Family: none)	o.,	1-14

3